Kathryn Lumb

Counsel - Boston

Kathryn Lumb
Download Media Photo

Contact Information


As counsel in Foley Hoag's Business Department, Kathryn Lumb focuses on advising our life sciences clients with respect to various licensing matters such as research, development and commercialization agreements; manufacturing and supply agreements; co-development agreements; distribution agreements; and material transfer and other technology agreements. Kathryn has extensive experience with IP advice and counseling, patent filing and prosecution, patent litigation, regulatory exclusivity and guidance, and trademark and copyright matters.

Education:

  • George Washington University Law School, J.D., 1998
  • Lehigh University, B.S., Molecular Biology, 1993

Representative Experience

  • Represented HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company with expertise in immune modulation and single cell science, in a $1.1B+ agreement to exclusively license its Galectin-9 program and grant an exclusive option to its CXCR5 and CCR8 programs.
  • Represented Ginkgo Bioworks, the organism company, in a gene therapy collaboration and license agreement with Biogen to redefine the industry standard for manufacturing and develop a next-generation recombinant adeno-associated virus (AAV) production platform, for an upfront payment of $5 million and up to $115 million in future milestone payments.
  • Represented Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust and expansive lipid nanoparticle (LNP) patent estate, in a global collaboration and license agreement with Takeda Pharmaceutical Company Limited.
  • Represented Anji Pharma in a License Transfer and Royalty Agreement with LipimetiX Development, transferring all rights worldwide (in addition to the previously sublicensed territory of China, Hong Kong and Taiwan) to their Apo E mimetic peptides program, for upfront cash payments and a royalty on future commercial sales. 
  • Represented Dogma Therapeutics in the sale of its oral PCSK9 program to global biopharmaceutical company AstraZeneca for upfront as well as downstream payments linked to global regulatory and commercial milestones. 
  • Represented Dicerna Pharmaceuticals (Nasdaq: DRNA) in a global collaboration agreement with Novo Nordisk A/S (NYSE: NVO) to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases. Under the terms of the agreement, Dicerna will receive an upfront payment of $175 million, a $50 million equity investment and up to $357.5 million per target in development, regulatory, and commercialization milestone payments.
  • Represented Bridge Biotherapeutics in a collaboration and license agreement in excess of €1.1 billion in upfront and milestone payments, plus royalties, with Boehringer Ingelheim to develop Bridge Biotherapeutics’ autotaxin inhibitor BBT-877 for idiopathic pulmonary fibrosis (IPF) and other fibrosing interstitial lung diseases. 
  • Represented LegoChem Bio in a $400+ million multi-target research collaboration and license agreement with Takeda Pharmaceutical Company Limited (NYSE: TAK).
  • Advised Applied Genetic Technologies Corporation (Nasdaq: AGTC) in a strategic collaboration with Otonomy, Inc. (Nasdaq: OTIC) to co-develop and co-commercialize an adeno-associated virus (AAV)-based gene therapy.

Professional Experience

  • Northeast Intellectual Property, Co-founder
  • Elan Pharmaceuticals, Chief Intellectual Property Officer
  • Pfizer Inc., Assistant General Counsel

Involvement

  • Biotechnology Industry Organization, member
  • Boston Patent Law Association, member
     

 

Add to Bio Folder

Download Bio

Bar Admissions

  • Illinois

Court Admissions

  • U.S. Patent & Trademark Office (Agency)